Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)
14 September 2022 - 08:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 6-K/A
Amendment No. 1
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report:
September 2022
Commission File Number: 001-39179
Addex Therapeutics
Ltd
(Translation of registrant’s name into English)
Chemin des Mines 9,
CH-1202 Geneva,
Switzerland
(Address of principal executive
office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ☐
EXPLANATORY NOTE
This Report on Form 6-K/A (the “Amendment”) amends the Report
on Form 6-K filed on August 18, 2022 (the “Original 6-K”)
containing the Unaudited Interim Condensed Consolidated Financial
Statements of Addex Therapeutics Ltd., (the “Company”) as of
and for the six months ended June 30, 2022. The purpose
of this Amendment is solely to provide the Company’s Unaudited
Interim Condensed Consolidated Financial Statements as of and for
the six months ended June 30, 2022 formatted in Inline
eXtensible Business Reporting Language (“iXBRL”) in accordance with
Rule 405 of Regulation S-T and paragraph C.(6)(a)(ii) of
the General Instructions to Form 6-K, attached hereto as
Exhibit 99.1. Such Unaudited Interim Condensed Consolidated
Financial Statements were previously filed without iXBRL as exhibit
99.1 to the Original 6-K.
Except as described above, this Amendment speaks as of the original
filing date of the Original 6-K and does not amend, update or
restate any information set forth in the Original 6-K or reflect
any events that occurred subsequent to the original filing date of
the Original 6-K.
The information contained in this Form 6-K, including Exhibits
99.1 and 101, is hereby incorporated by reference into the
Company’s Registration Statement on Form F-3 (File
No. 333- 255089) and the registration statement on Form S-8
(Registration No.333-255124).
|
|
|
|
Exhibit
|
|
|
99.1
|
Unaudited Interim Condensed Consolidated Financial Statements as of
and for the six months ended June 30, 2022
|
|
101.INS
|
The following materials from this Report on Form 6-K are
formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Unaudited Interim Condensed Consolidated Balance Sheets as
of June 30, 2022 and December 31, 2021;
(ii) Unaudited Interim Condensed Consolidated Statements of
Comprehensive Loss for the three-month and the six-month periods
ended June 30, 2022 and 2021; (iii) Unaudited Interim
Condensed Consolidated Statements of Changes in Equity for the
six-month periods ended June 30, 2022 and 2021;
(iv) Unaudited Interim Condensed Consolidated Statements of
Changes in Equity for the three-month periods ended June 30,
2022 and 2021; (v) Unaudited Interim Condensed Consolidated
Statements of Cash Flows for the six-month periods ended
June 30, 2022 and 2021; and (vi) Unaudited Notes to
the Interim Condensed Consolidated Financial Statements for the
three-month and six-month periods ended June 30, 2022.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this amended report to be
signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
|
|
|
Addex Therapeutics Ltd
|
|
|
(Registrant)
|
|
|
|
|
Date: September 14, 2022
|
/s/ Tim Dyer
|
|
|
Tim Dyer
|
|
|
Chief Executive Officer
|
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Feb 2023 to Mar 2023
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2022 to Mar 2023
